These lines also showed reduced phosphorylation levels of the direct and indirect Akt targets GSK-3 α/β and p70S6K, revealing that sorafenib may severely affect the PI3K/Akt pathway in some lymphoma cell lines (Figure 3A–B). Here, AKT1 is linked to lymphoma.